|
Martin et al. [29]
|
Retrospective controlled study, 12 months
|
26 HCV(+) men versus 20 HCV(-) (19 men, 1 woman)
|
Disulfiram 1500 mg/week, supervised
|
Hepatic safety of disulfiram as measured by AST/ALT
|
1–No statistically or clinically significant elevations of AST/ALT for the HCV(+) group at any time point
|
No patients taken off disulfiram; no subjects reached 3 times to upper limit for AST/ALT
|
| | | | |
1–In HCV(+) group over time; 2–Compared to HCV(-) group
|
2–Between-group means were identical at all time points
| |
|
Saxon et al. [27]
|
Prospective study of 3 months
|
57 male veterans; 18 HCV(+) and 39 HCV(-) with elevation of AST/ALT
|
Disulfiram
|
Hepatic safety of disulfiram as measured by elevations in AST/ALT in
|
Clinically relevant elevation (2x the baseline and 3x the normal) in:
|
No hepatitis or hepatic failure, although some patients did have a significant elevation
|
| | | | |
1–HCV(+)
|
1–4/18 HCV(+)
| |
| | | | |
2–HCV(-) with baseline elevation of AST/ALT
|
2–1/39 HCV(-)
| |
|
Leggio et al. [31]
|
Post-hoc analysis of a randomized placebo-controlled trial of cirrhotic patients [30], 12 weeks
|
24 HCV(+) cirrhotic patients; 12 receiving baclofen versus 12 receiving placebo
|
Baclofen 30 mg daily versus placebo
|
1–Efficacy of baclofen in HCV(+) cirrhotic patients
|
1–Significantly more abstinence in baclofen group (83,3% vs. 25%; p = 0,0123)
|
No hepatic or renal adverse events. General side effects were not more frequent compared to placebo
|
| | | | |
2–Hepatic safety of baclofen as measured by biochemical liver function tests
|
2–Higher albumin and trend toward decreased INR in baclofen group; no effect on AST/ALT/GGT
| |
